Dr. Dmitriy Zamarin completed his MD PhD studies in 2008 at the Mount Sinai School of Medicine under the mentorship of Dr. Peter Palese, where his research was focused on the mechanisms underlying influenza virus pathogenicity. He pursued residency training in internal medicine at the Mount Sinai Hospital and fellowship training in hematology/oncology at MSKCC. During fellowship, he conducted studies under the mentorship of Drs. James Allison and Jedd Wolchok. His research led to seminal findings delineating mechanisms of anti-tumor immunity activated by oncolytic viruses. In 2014 he joined the faculty of the Gynecologic Medical Oncology Service at MSKCC, where he served as the Translational Research Director. At MSKCC, Dr. Zamarin led a laboratory research group focusing on immunology and immunotherapy of gynecologic cancers and established a multi-disciplinary research program for comprehensive immunogenomic profiling of gynecologic cancers. Taking advantage of this infrastructure, he developed and executed a number of investigator-initiated and cooperative group clinical trials in gynecologic cancers with both clinical and translational endpoints. In September of 2023, he was recruited to Icahn School of Medicine as the Section Chief of Gynecologic Medical Oncology.

Dr. Zamarin has participated in multiple national and international research committees and holds leadership positions in several of them, including his roles as the Chair of the Research Management Committee of the Canadian BioCanRx Research Foundation, Translational Chair of the NRG Oncology Cervical Cancer Committee, Core Member of the NRG Developmental Therapeutics Committee, and Member of the NCI Ovarian Cancer Task Force. He has co-authored over 140 manuscripts, many in leading professional journals. His work has been supported by multiple grants, including awards from the Damon Runyon Cancer Research Foundation, Conquer Cancer Foundation, Ovarian Cancer Research Alliance, Department of Defense and R01 grants from the National Cancer Institute.